A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.
Twenty adult patients with high-risk leukaemia underwent allogeneic haemopoietic stem cell transplantation after melphalan, busulphan and total body irradiation followed by short-term methotrexate and low-dose cyclosporine or tacrolimus. Three patients developed veno-occlusive disease and no patient developed renal dysfunction. Seven patients experienced grade II-IV acute graft-versus-host disease (aGVHD) and five patients experienced grade III-IV. The 3-year probabilities of relapse and leukaemia-free survival were 22 +/- 11% (95% confidence interval) and 50 +/- 11%, respectively. These data suggest that this preconditioning regimen followed by a low-dose immunosuppressant provided a more anti-leukaemic effect without increased regimen-related toxicity and aGVHD.
Murata
M
M
Division of Haematology, Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Nishida
T
T
Haneda
M
M
Kanie
T
T
Taji
H
H
Iida
H
H
Suzuki
R
R
Hamaguchi
M
M
Minami
S
S
Kodera
Y
Y
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage; D016572:Cyclosporine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*; D014916:Whole-Body Irradiation / Q000379:methods*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D002066:Busulfan; D008558:Melphalan; D016559:Tacrolimus